Gilead Sciences (NASDAQ:GILD) announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for lenacapavir to be used as pre-exposure prophylaxis (PrEP) against HIV.
This accelerated review endorses lenacapavir to lower the risk of sexually transmitted HIV-1 infection in adults and adolescents considered at higher risk of HIV-1 exposure.
The European Commission is expected to make a final approval decision for this use later in 2025.
The CHMP’s positive opinion marks a key milestone for Gilead’s efforts to bring its HIV prevention treatment to the European market.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.